New Delhi: Shilpa Medicare Limited has reported positive results from its Phase 3 clinical trial of OERIS™-Ondansetron Extended-Release Injection, a once-weekly injectable designed to prevent chemotherapy-induced nausea and vomiting or CINV. The pivotal trial, coded SMLINJ011, achieved all its primary and secondary endpoints, marking an important step in strengthening the company’s oncology-supportive care portfolio.

The multicentre, randomised, double-blind study was carried out across major oncology centres in India, enrolling 240 patients undergoing moderate or highly emetogenic chemotherapy. Results showed that 89 per cent of participants in the OERIS™ group achieved a complete response, no vomiting episodes within 120 hours after chemotherapy, compared to 82 per cent in the conventi

See Full Page